GYRE Trademark
Trademark Overview
On Monday, June 23, 2025, a trademark application was filed for GYRE with the United States Patent and Trademark Office. The USPTO has given the GYRE trademark a serial number of 99248264. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, June 2, 2026. This trademark is owned by Gyre Therapeutics, Inc.. The GYRE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations for the treatment and prevention of chronic obstructive pulmonary disease, pulmonary arterial hypertension, acute liver failure, acute-on-chronic liver failure, liver fibrosis, metabolic dysfunction associated fatty liver disease, nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, lung fibrosis, organ fibrosis, and inflammatory diseases; each of the foregoing excluding those featuring oral vaporizers for smoking purposes and oral vaporizers for smokers
Conducting early evaluations in the field of new pharmaceuticals; Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Testing of pharmaceuticals; each of the foregoing excluding those featuring oral vaporizers for smoking purposes and oral vaporizers for smokers
General Information
| Serial Number | 99248264 |
| Word Mark | GYRE |
| Filing Date | Monday, June 23, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, June 2, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 23, 2026 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the treatment and prevention of chronic obstructive pulmonary disease, pulmonary arterial hypertension, acute liver failure, acute-on-chronic liver failure, liver fibrosis, metabolic dysfunction associated fatty liver disease, nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, lung fibrosis, organ fibrosis, and inflammatory diseases; each of the foregoing excluding those featuring oral vaporizers for smoking purposes and oral vaporizers for smokers |
| Goods and Services | Conducting early evaluations in the field of new pharmaceuticals; Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Testing of pharmaceuticals; each of the foregoing excluding those featuring oral vaporizers for smoking purposes and oral vaporizers for smokers |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 23, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 23, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | Monday, October 30, 2023 |
| First Use In Commerce Date | Monday, October 30, 2023 |
Trademark Owner History
| Party Name | Gyre Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130
US |
Trademark Events
| Event Date | Event Description |
| Monday, June 23, 2025 | NEW APPLICATION ENTERED |
| Monday, June 23, 2025 | APPLICATION FILING RECEIPT MAILED |
| Thursday, October 30, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, November 12, 2025 | ASSIGNED TO EXAMINER |
| Wednesday, November 19, 2025 | NON-FINAL ACTION WRITTEN |
| Wednesday, November 19, 2025 | NON-FINAL ACTION E-MAILED |
| Wednesday, November 19, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, February 13, 2026 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, February 13, 2026 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, May 4, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, May 4, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, May 4, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 22, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, May 22, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Friday, May 22, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Friday, May 22, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, May 27, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
